Fig. 3: Inhibition of the BET bromodomain mitigates the progression of PVR.

A Schematic view of experimental strategy in the PVR mouse model. B The size and zeta potential of eNano-JQ1. C Transmission electron microscopy image of eNano-JQ1. Scale bar: 100 nm. This was repeated at least three times independently with similar results. D The stability was evaluated by measuring changes in size and polydispersity index (PDI) at different time (left) and dilution ratio (right). n = 3 independent experiments. Data were represented as means ± SEMs. E Release profile of JQ1 from eNano-JQ1. F Representative fundus imaging and OCT image of mice. The pathological changes were indicated with black arrows. The retinal folds or tractional area was circled with yellow dotted lines, and PVR membrane was marked with an asterisk (*). G Representative H&E staining of eye sections from mice with indicated treatment (left). The black dotted lines indicated pathological changes, and PVR membrane was marked with an asterisk (*). Scale bar: 250 μm. Quantification of PVR severity (right). n = 7, 8, 7 samples, respectively. P = 0.0002, 0.0009 were determined by two-tailed Mann–Whitney test. ***P < 0.001. H Western blot analysis (up) and quantification (down) of αSMA in eyecup tissues from normal and PVR mice treated with vehicle or eNano-JQ1. n = 3 samples. Data are represented as means ± SEMs. P values = 0.005, 0.0356 were determined by one-way ANOVA multiple comparisons test. *P < 0.05, **P < 0.01. I Representative immunofluorescent staining of αSMA in mouse eye sections (left). The yellow dotted lines indicated the whole eye. The white dotted lines indicated PVR membrane. Scale bars: yellow 100 μm, white 20 μm. Quantification of mean fluorescence integrated density of αSMA (right). n = 5, 6, 6 samples, respectively. Data are represented as means ± SEMs. P values < 0.0001 were determined by one-way ANOVA multiple comparisons test. ****P < 0.0001. Source data are provided as a Source Data file.